# Cell Therapy * **Definition:** A type of treatment that involves the use of living cells to prevent, treat, or cure diseases, often through engineered or modified cells to repair or replace damaged tissues or to enhance the immune response against diseases such as cancer. * **Taxonomy:** Healthcare Topics / Cell Therapy ## News * Selected news on the topic of **Cell Therapy**, for healthcare technology leaders * 14K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/11/2025 | [**Understanding the Potential of Stem Cell Therapy for Diabetes Type 2**](https://www.healthline.com/health/stem-cell-for-diabetes-type-2) | [[Healthline]] | | 4/23/2025 | [**High Response Rate in Myeloma With Novel CAR-T After Anti-BCMA Failure**](https://www.medpagetoday.com/hematologyoncology/myeloma/115242) | [[Medpage Today]] | | 4/14/2025 | [**Cancer Treatment Revolutionized by Cellular Engineering, and Nanotechnology Redefined ...**](https://finance.yahoo.com/news/cancer-treatment-revolutionized-cellular-engineering-193100376.html) | [[Yahoo Finance]] | | 3/17/2025 | [**AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition**](https://medcitynews.com/2025/03/astrazeneca-esobiotec-acquisition-allogeneic-cell-therapy-cancer-azn/) | [[MedCity News]] | | 3/5/2025 | [**CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum - Yahoo Finance**](https://finance.yahoo.com/news/car-t-cell-therapy-clinical-180000195.html) | [[Yahoo Finance]] | | 2/27/2025 | [**BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions**](https://www.globenewswire.com/news-release/2025/02/27/3033949/0/en/BioCardia-Announces-Primary-Outcome-Measures-Data-Freeze-in-CardiAMP-Heart-Failure-Trial-for-Presentation-at-the-American-College-of-Cardiology-2025-Scientific-Sessions.html) | [[Globe Newswire]] | | 2/22/2025 | [**Harnessing the Microbiome May Help Reduce CAR T-Cell Therapy Toxicity**](https://www.pharmacytimes.com/view/harnessing-the-microbiome-may-help-reduce-car-t-cell-therapy-toxicity) | [[Pharmacy Times]] | | 2/21/2025 | [**Intestinal Microbiome May Play a Role in CAR T-Cell Therapy Outcomes**](https://www.pharmacytimes.com/view/intestinal-microbiome-may-play-a-role-in-car-t-cell-therapy-outcomes) | [[Pharmacy Times]] | | 2/3/2025 | [**Autologous Cell Therapy Market to Hit Valuation of US$ 44.55 Billion By 2033 - Astute Analytica**](https://finance.yahoo.com/news/autologous-cell-therapy-market-hit-133000525.html) | [[Yahoo Finance]] | | 1/16/2025 | [**Cell Therapy Technologies Market Forecasts 2024-2029: Advancements in Gene ... - Yahoo Finance**](https://finance.yahoo.com/news/cell-therapy-technologies-market-forecasts-094300127.html) | [[Yahoo Finance]] | | 1/3/2025 | [**Cell Therapy and Gene Therapy CDMO Market to Reach USD 11.11 Billion by 2030 - Discover Growth Trends and Insights - Valuates Reports**](https://www.prnewswire.com/news-releases/cell-therapy-and-gene-therapy-cdmo-market-to-reach-usd-11-11-billion-by-2030--discover-growth-trends-and-insights--valuates-reports-302341836.html) | [[PR Newswire]] | | 12/9/2024 | [**Stem Cell Therapy Market to Worth Over US$ 2,612.92 Million By 2033 - Astute Analytica**](https://finance.yahoo.com/news/stem-cell-therapy-market-worth-173000700.html) | [[Yahoo Finance]] | | 12/2/2024 | [**Allogeneic Stem Cell Therapy Segment is Expected to Reach US$1 Billion by 2030 with a ...**](https://finance.yahoo.com/news/stem-cell-therapy-strategic-business-092300629.html) | [[Yahoo Finance]] | | 11/18/2024 | [**CAR T-Cell Therapy Market to Surpass Valuation of USD 106.06 Billion by 2031**](https://finance.yahoo.com/news/car-t-cell-therapy-market-122300887.html) | [[Yahoo Finance]] | | 11/18/2024 | [**Stem Cell Therapy Market Expected To Reach 31.33 Billion, Growing at 11.20AGR By 2032 - Introspective Market Research**](https://www.globenewswire.com/news-release/2024/11/18/2982807/0/en/Stem-Cell-Therapy-Market-Expected-To-Reach-31-33-Billion-Growing-at-11-20-CAGR-By-2032-Introspective-Market-Research.html) | [[Globe Newswire]] | | 11/17/2024 | [**Stem Cell Therapy Market Expected To Reach 31.33 Billion, Growing at 11.20AGR By 2032 - Introspective Market Research**](https://finance.yahoo.com/news/stem-cell-therapy-market-expected-133600779.html) | [[Yahoo Finance]] | | 11/11/2024 | [**Largest T cell clinical trial in solid tumors explores potential for precision immunotherapy**](https://medicalxpress.com/news/2024-11-largest-cell-clinical-trial-solid.html) | [[MedicalXpress]] | | 11/11/2024 | [**NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment - DelveInsight**](https://www.prnewswire.com/news-releases/nk-cell-therapy-clinical-trial-pipeline-appears-robust-with-140-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-302300917.html) | [[PR Newswire]] | | 11/11/2024 | [**Largest T cell clinical trial in solid tumors explores potential for precision immunotherapy**](https://medicalxpress.com/news/2024-11-largest-cell-clinical-trial-solid.html?deviceType=desktop) | [[MedicalXpress]] | | 11/11/2024 | [**VANCE trial marks milestone in t cell therapy for solid tumors**](https://www.news-medical.net/news/20241111/VANCE-trial-marks-milestone-in-t-cell-therapy-for-solid-tumors.aspx) | [[News Medical Net]] | | 11/11/2024 | [**NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment - DelveInsight**](https://finance.yahoo.com/news/nk-cell-therapy-clinical-trial-223100147.html) | [[Yahoo Finance]] | | 11/8/2024 | [**MD Anderson launches new institute for advancing cell therapy**](https://www.news-medical.net/news/20241108/MD-Anderson-launches-new-institute-for-advancing-cell-therapy.aspx) | [[News Medical Net]] | | 10/2/2024 | [**Adoptive Cell Therapy Clinical Trials Report, 2024: Trends, Key Segments, Top Sponsors ...**](https://finance.yahoo.com/news/adoptive-cell-therapy-clinical-trials-132900509.html) | [[Yahoo Finance]] | | 9/24/2024 | [**Global Cell Therapy Biomanufacturing Market Projected to Reach $16.7 Billion by 2029**](https://www.prnewswire.com/news-releases/global-cell-therapy-biomanufacturing-market-projected-to-reach-16-7-billion-by-2029--302257609.html) | [[PR Newswire]] | | 8/26/2024 | [**CD Antigen Cancer Therapy Market 2024: Trends, Innovations, And Growth Outlook**](https://www.barchart.com/story/news/28220220/cd-antigen-cancer-therapy-market-2024-trends-innovations-and-growth-outlook) | barchart.com | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **Cellistic**: A company specializing in 3D bioreactor-based manufacturing platforms for cell therapy production. - **MedTherapy**: A biotechnology company focused on CAR-T cell therapy, known for reducing manufacturing time and costs. - **Cellares**: Developing automated cell therapy manufacturing platforms to enhance efficiency. - **GC Cell Corporation**: A company known for its autologous T cell therapy, Immuncell-LC, approved in Korea. - **Merck KGaA**: Involved in the development of cell therapy technologies. - **Thermo Fisher Scientific**: Provides solutions for cell therapy manufacturing. - **SCG Cell Therapy**: Collaborating with A*STAR to advance iPSC technology for novel therapies. - **ExCellThera**: A company developing UM171 cell therapy for hematological malignancies, recently accepted for EMA review. - **Multiply Labs**: A company specializing in automating cell therapy production using robotics. - **University of Texas MD Anderson Cancer Center**: A prominent institution advancing cell therapy research and development. - **Captain T Cell**: A company developing TCR-T cell therapies for solid tumors, collaborating with Charles River for vector production. - **Cellino Biotech**: A company focused on developing advanced biomanufacturing technology for personalized regenerative medicines, utilizing AI and laser technology to automate cell therapy production. - **Danaher Corporation**: Key player in the cell therapy technologies market. - **CareDx**: A precision medicine company partnering with TC BioPharm to analyze pharmacokinetics in cell therapy for blood cancers. - **Trailhead Biosystems**: A startup specializing in iPSC-derived human cells for drug discovery and cell therapy. - **BrightPath Bio**: A company focused on developing allogeneic CAR-T therapies, collaborating with Cellistic for scalable manufacturing solutions. ### Partnerships and Collaborations - **SCG Cell Therapy and A*STAR**: Joint laboratories focused on iPSC technology and talent development in cellular immunotherapy. - **BrightPath Bio and Cellistic**: Partnering to develop iPSC-derived CAR-iNKT cells for clinical trials targeting multiple myeloma. - **Matica Biotechnology and CytoImmune**: Partnering to advance clinical cell therapy programs, focusing on viral vector production and cell therapy manufacturing. - **Kytopen and Aldevron**: Collaboration to enhance cell therapy manufacturing through innovative technologies. - **Multiply Labs and Legend Biotech**: Formed a collaboration to automate cell therapy production using robotics. - **Akadeum Life Sciences**: Collaborating with industry players to enhance workflows in cell therapy manufacturing. - **Cellares and Sony Corporation**: Collaborating to develop advanced flow cytometry-based cell analysis and sorting solutions for automated cell therapy manufacturing. - **Excellos and Galapagos**: Collaboration for manufacturing CAR-T cell therapy candidates using a decentralized manufacturing platform. - **Cellares and Sony**: Integration of Sony's technologies into Cellares' manufacturing platform to improve cell therapy production. - **Charles River Laboratories and Captain T Cell**: Collaboration for plasmid DNA and retrovirus vector production to support TCR-T cell therapy development. - **American Red Cross and Accellix**: Partnership to improve characterization of source materials for cell therapy using automated flow cytometry. - **Kite Pharma and Cytiva**: Partnership to develop a new cell therapy manufacturing platform. - **NewBiologix and U.S. Operations**: Launching a subsidiary to enhance support for gene and cell therapy companies in the U.S. market. - **Aurigene Pharmaceutical Services and Edity Therapeutics**: Collaboration to provide cell therapy discovery services for clinical development. - **Pluri Inc. and Kadimastem**: Agreement to produce cell therapy products for ALS and diabetes, enhancing manufacturing capacity. - **Cellino Biotech and ARPA-H**: Cellino received $25 million in funding to develop advanced biomanufacturing technology for personalized regenerative therapies. ### Innovations, Trends, and Initiatives - **NK Cell Therapy Advancements**: Utilizing genetic engineering and CAR technology to enhance specificity and efficacy in treating various cancers. - **CAR-T Cell Therapy**: An innovative immunotherapy that genetically modifies T cells to target and kill cancer cells, showing promise in treating various cancers, especially in pediatrics. - **CAR-T Cell Therapy Innovations**: Exploring armored CARs and bispecific CARs to improve targeting and resilience against solid tumors. - **Exosome Initiatives**: Advancements in exosome technology are driving growth in the stem cell therapy market. - **Institute for Cell Therapy Discovery & Innovation**: Launched by MD Anderson to advance impactful cell therapies and integrate research efforts. - **Combined Cell Therapy for Kidney Transplants**: Innovative approach reducing immune reactions without lifelong immunosuppression. - **Automated Cell Therapy Manufacturing**: The development of fully automated systems like Cellares' Cell Shuttle aims to streamline and enhance the efficiency of cell therapy production. - **Allogeneic Therapies**: Growing interest in allogeneic CAR-T therapies to improve accessibility and reduce manufacturing complexities. - **Focus on Allogeneic Therapies**: Research is increasingly directed towards developing allogeneic CAR T-cell therapies to improve accessibility and affordability. - **Advancements in CAR T-cell Therapy**: Over 180 companies are developing CAR T-cell therapies, with innovations targeting solid tumors and autoimmune diseases. - **Gene and Cell Therapy Institute**: Launched by Mass General Brigham to facilitate the translation of scientific discoveries into clinical applications. - **Allogeneic Cell Therapy Market**: Expected to grow significantly, with a CAGR of 24.5%, focusing on donor cell therapies. - **CRISPR-Cas9 Technology**: Key driver in personalized cell therapy, enabling precise gene editing. - **Decentralized Manufacturing**: Efforts to decentralize CAR-T therapy production to reduce vein-to-vein times and improve patient access. - **VANCE Trial**: The largest clinical trial of T cell therapy for solid tumors, showcasing Singapore's capabilities in global cell therapy trials. - **Thermo Fisher's CTS Detachable Dynabeads**: New product designed to enhance the isolation and activation of T cells for CAR-T therapies. - **CAR T-cell Therapy Growth**: Projected market growth from USD 5.5 billion in 2024 to USD 29.0 billion by 2029, driven by technological advancements. - **Emergence of NK Cell Therapies**: NK cell therapies are gaining traction, with over 180 therapies in trials, expected to be approved by 2028. ### Challenges and Concerns - **Ethical Issues**: Concerns surrounding the use of stem cells and the ethical implications of cell therapy development. - **High Therapy Costs**: CAR T-cell therapies face challenges due to their high costs and potential adverse effects. - **Market Competition**: The rapidly growing cell therapy market is characterized by intense competition and the need for continuous innovation. - **High Costs**: The development and manufacturing costs of personalized cell therapies can exceed $1 million per dose, limiting patient access. - **Cytopenia Management**: Cytopenia remains a significant adverse event in CAR T-cell therapy, necessitating better management strategies. - **T-cell Exhaustion in CAR-T Therapy**: Research indicates that excessive IL-4 production by CAR-T cells can lead to treatment failure, highlighting the need for improved therapeutic strategies. - **High Treatment Costs**: The significant costs associated with cell therapies limit access, particularly in emerging markets. - **Access Issues**: Despite advancements, only a fraction of patients can access cell therapies due to high costs and logistical challenges. - **Supply Limitations**: The number of patients benefiting from CAR-T therapy is limited by the insufficient supply of autologous cell therapy. - **Manufacturing Complexities**: The cell therapy sector faces significant challenges in manufacturing processes, which are often labor-intensive and costly. - **Market Viability**: Concerns about the viability of cell therapies for autoimmune conditions have arisen following leadership changes and stock performance issues at Kyverna Therapeutics. - **Manufacturing Scalability**: The need for scalable manufacturing solutions in cell therapy production to meet increasing demand and ensure quality. - **Immunosuppressive Tumor Environments**: Challenges in NK cell therapy include overcoming the immunosuppressive nature of tumor microenvironments. - **Regulatory Compliance**: Ensuring adherence to GMP standards and regulatory guidelines is critical for successful cell therapy delivery. - **Cost and Accessibility**: High costs and limited effectiveness against solid tumors remain significant barriers to widespread adoption of CAR T-cell therapies. - **Manufacturing Complexity**: The complexity of CAR T-cell therapy manufacturing poses challenges for scalability and accessibility. - **Market Setbacks**: Declining interest in cell therapies and the need for improved effectiveness and delivery methods to regain market acceptance. - **Patient-Specific Factors**: Resistance to CAR-T therapy can be influenced by prior treatments and overall health, complicating patient outcomes. - **Safety Assessments and Cost Control**: Ongoing innovation and collaboration are necessary to address safety and cost concerns in cell therapy. ## Related Topics [[Gene Therapy]]; [[Gene Therapies]]; [[Cancer Therapy]]